Photo taken from Erman Akkus/X
Dec 29, 2023, 16:34
Erman Akkus: KEYNOTE-585 – although pathological complete response improved, no survival advantage
Erman Akkus, Medical Oncology Fellow at Ankara University, shared on X/Twitter:
“KEYNOTE-585: Neoadjuvant and adjuvant pembro+chemo in locally advanced gastric/GE cancer in The Lancet Oncology.
- 804 patients
- 3xPembro/placebo+chemo >surgery > 3xPembro/placebo+chemo > 11pembro/placebo
- pCR: 12.9% vs 2%, p<0.00001
- Median event free survival: 44.4 mo vs 25.3 mo (HR: 0.81, p=0.01)
- Median OS: 60.7 mo vs 58 mo, p=0.17
Although pathological complete response improved, no survival advantage.”
Source: Erman Akkus/X
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Dec 21, 2024, 13:12
Dec 21, 2024, 13:05
Dec 21, 2024, 12:18
Dec 21, 2024, 11:52
Dec 21, 2024, 11:30
Dec 21, 2024, 11:25